Holen Sie sich die Stockscreener-App
2.11
2.43%
0.05
Handel nachbörslich:
2.11
Schlusskurs vom Vortag:
$2.06
Offen:
$2.08
24-Stunden-Volumen:
1.27M
Relative Volume:
0.65
Marktkapitalisierung:
$205.98M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.7326
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
+4.46%
1M Leistung:
-2.76%
6M Leistung:
-33.02%
1J Leistung:
+49.65%
1-Tages-Spanne:
$2.06
$2.17
1-Wochen-Bereich:
$2.02
$2.43
52-Wochen-Spanne:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.11 | 201.09M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well - simplywall.st
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Street Watch: Is Editas Medicine Inc stock a falling knife or bargain buy2025 Major Catalysts & Daily Oversold Bounce Ideas - baoquankhu1.vn
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Hedge Fund Bets: Can Editas Medicine Inc disrupt its industry2025 Buyback Activity & Precise Trade Entry Recommendations - baoquankhu1.vn
Fed Watch: Can Editas Medicine Inc. maintain sales growthJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Recap Report: Can Editas Medicine Inc. stock surprise with earnings upsidePortfolio Risk Summary & Low Risk Investment Opportunities - Bộ Nội Vụ
Retail Surge: Is Editas Medicine Inc stock affected by interest rate hikesJuly 2025 Decliners & Real-Time Volume Analysis Alerts - Bộ Nội Vụ
Inflation Data: Will Editas Medicine Inc stock remain a Wall Street favoriteJuly 2025 Recap & Detailed Earnings Play Strategies - moha.gov.vn
Is Editas Medicine Inc. stock overvalued by current metricsQuarterly Risk Review & AI Powered Trade Plan Recommendations - ulpravda.ru
Can Editas Medicine Inc. stock surprise with earnings upsideQuarterly Market Summary & Free Safe Entry Trade Signal Reports - Улправда
Will Editas Medicine Inc. stock remain a Wall Street favoriteMarket Sentiment Review & AI Driven Price Predictions - Улправда
Is Editas Medicine Inc. stock in correction or buying zone2025 Growth vs Value & Reliable Entry Point Alerts - Улправда
Can Editas Medicine Inc. stock attract ESG capital inflowsWall Street Watch & Real-Time Buy Signal Notifications - ulpravda.ru
Is Editas Medicine Inc. stock affected by interest rate hikesShort Setup & Reliable Volume Spike Trade Alerts - Улправда
Is Editas Medicine Inc. stock ready for breakout2025 Valuation Update & Free Expert Approved Momentum Trade Ideas - Улправда
Street Watch: Can Editas Medicine Inc. (8EM) stock expand revenue streams2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - Улправда
Aug Catalysts: Why Editas Medicine Inc. (8EM) stock could rally stronglyQuarterly Profit Summary & Free Verified High Yield Trade Plans - Улправда
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Alka Securities LimitedMarket Sentiment Shifts & Free Realize Exceptional Returns - earlytimes.in
Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9%Should You Sell? - MarketBeat
Editas Medicine (EDIT) price target increased by 22.78% to 4.95 - MSN
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Would You Still Hold Editas Medicine Stock If It Fell Another 30%? - Trefis
What margin trends mean for Editas Medicine Inc. stockIPO Watch & Weekly Chart Analysis and Guides - DonanımHaber
How Editas Medicine Inc. stock compares to growth peersPortfolio Profit Report & Precise Entry and Exit Recommendations - Bölüm Sonu Canavarı
Why Editas Medicine Inc. stock is seen as undervaluedOptions Play & Advanced Swing Trade Entry Alerts - DonanımHaber
Editas Medicine (LTS:0IFK) EV-to-FCF : -0.48 (As of Dec. 18, 2025) - GuruFocus
S P Trends: How Editas Medicine Inc stock compares to growth peersWeekly Profit Recap & Consistent Profit Trading Strategies - moha.gov.vn
Editas Medicine (FRA:8EM) EV-to-OCF : -0.45 (As of Dec. 18, 2025) - GuruFocus
Market Rankings: What margin trends mean for Editas Medicine Inc. stockIPO Watch & Capital Efficiency Focused Strategies - moha.gov.vn
Editas (EDIT) down 8.3% since last earnings report: Can it rebound? - MSN
Editas Medicine Earnings Notes - Trefis
What analysts say about Editas Medicine Inc stockTechnology Stock Trends & Small Budget Trading Plans - earlytimes.in
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? - sharewise.com
Cell & Gene Therapy Market to Reach USD 105.83 Billion by 2033 - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95 - Nasdaq
Editas Medicine (EDIT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock - MarketBeat
Trend Recap: Is Editas Medicine Inc. (8EM) stock supported by free cash flowJuly 2025 Patterns & High Accuracy Swing Trade Signals - moha.gov.vn
What valuation ratios show for Editas Medicine Inc. (8EM) stockEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
CEO O'Neill Surrenders 5,603 Of Editas Medicine Inc [EDIT] - TradingView
Editas Medicine CEO Sells Shares to Meet Tax Obligations - TradingView
How Editas Medicine Inc. (8EM) stock performs in easing cyclesJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Will Editas Medicine Inc. (8EM) stock beat Nasdaq index returns2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Is Editas Medicine Inc. (8EM) stock positioned for digital growth eraMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
CEO O'Neill Files To Sell 7,000 Of Editas Medicine Inc [EDIT] - TradingView
Euro India Fresh Foods Limited Forms Bullish Flag Upside AheadCovered Call Writing & Learn From the Strategies of Institutions - earlytimes.in
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):